ECSP066866A - Formas de dosificación y composiciones farmacéuticasreferencia a las solicitudes relacionadas - Google Patents
Formas de dosificación y composiciones farmacéuticasreferencia a las solicitudes relacionadasInfo
- Publication number
- ECSP066866A ECSP066866A EC2006006866A ECSP066866A ECSP066866A EC SP066866 A ECSP066866 A EC SP066866A EC 2006006866 A EC2006006866 A EC 2006006866A EC SP066866 A ECSP066866 A EC SP066866A EC SP066866 A ECSP066866 A EC SP066866A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical compositions
- related applications
- dosage forms
- compositions reference
- methods
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Esta invención se refiere, por ejemplo, a nuevas formulaciones y métodos para la liberación de 4-ciano-N-{(2R)-2-[4-(2,3-dihidro-benzo[1,4]dioxin-5il)-piperazin-1-il]-propil}-N-piridin-2-il-benzamida, sales farmacéuticamente aceptables de la misma, compuestos estructuralmente relacionados, y/o metabolitos; así como al uso de estas formulaciones y métodos para tratar enfermedades
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55462204P | 2004-03-19 | 2004-03-19 | |
US11/082,548 US20050215561A1 (en) | 2004-03-19 | 2005-03-17 | Pharmaceutical dosage forms and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066866A true ECSP066866A (es) | 2006-11-24 |
Family
ID=35094454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006866A ECSP066866A (es) | 2004-03-19 | 2006-09-19 | Formas de dosificación y composiciones farmacéuticasreferencia a las solicitudes relacionadas |
Country Status (13)
Country | Link |
---|---|
US (1) | US20050215561A1 (es) |
EP (1) | EP1730139A2 (es) |
JP (1) | JP2007529551A (es) |
KR (1) | KR20070085090A (es) |
AU (1) | AU2005225435A1 (es) |
BR (1) | BRPI0508975A (es) |
CA (1) | CA2560243A1 (es) |
EC (1) | ECSP066866A (es) |
IL (1) | IL178067A0 (es) |
MX (1) | MXPA06010730A (es) |
PE (1) | PE20060125A1 (es) |
TW (1) | TW200539879A (es) |
WO (1) | WO2005092307A2 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060287335A1 (en) * | 2000-11-28 | 2006-12-21 | Wyeth | Serotonergic agents for treating sexual dysfunction |
US20060223824A1 (en) * | 2000-11-28 | 2006-10-05 | Wyeth | Serotonergic agents |
US20070099931A1 (en) * | 2004-03-19 | 2007-05-03 | Wyeth | Pharmaceutical dosage forms and compositions |
WO2006093853A1 (en) * | 2005-03-01 | 2006-09-08 | Wyeth | Crystalline and amorphous 4-cyano-n{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride |
TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
PE20070334A1 (es) * | 2005-09-09 | 2007-05-08 | Wyeth Corp | Composiciones y formas de dosificacion farmaceuticas que comprende lecozotan |
WO2007089616A2 (en) | 2006-01-26 | 2007-08-09 | The University Of Rochester | Inhibiting amyloid-beta peptide/rage interaction at the blood-brain barrier |
TW200831096A (en) * | 2006-11-28 | 2008-08-01 | Wyeth Corp | Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof |
US20080199518A1 (en) * | 2006-11-28 | 2008-08-21 | Wyeth | Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution |
TW200846032A (en) * | 2007-02-16 | 2008-12-01 | Wyeth Corp | Sustained-release tablet formulations of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution |
JP5819800B2 (ja) * | 2012-10-31 | 2015-11-24 | 信越化学工業株式会社 | 高粘度ヒプロメロースを分散したコーティング液及び固形製剤の製造方法 |
JP6380922B2 (ja) * | 2016-05-30 | 2018-08-29 | 大正製薬株式会社 | チペピジンの経口用製剤 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
JPS6051106A (ja) * | 1983-08-31 | 1985-03-22 | Yamanouchi Pharmaceut Co Ltd | 塩酸アモスラロ−ル持続性製剤 |
GB8616669D0 (en) * | 1986-07-09 | 1986-08-13 | Merk Sharpe & Dohme Ltd | Pharmaceutical compositions |
US5523289A (en) * | 1991-04-15 | 1996-06-04 | Abbott Laboratories | Pharmaceutical composition |
MX9201991A (es) * | 1991-05-02 | 1992-11-01 | Jonh Wyeth & Brother Limited | Derivados de piperazina y procedimiento para su preparacion. |
GB9125900D0 (en) * | 1991-12-05 | 1992-02-05 | Wyeth John & Brother Ltd | Piperazine derivatives |
DE69425453T2 (de) * | 1993-04-23 | 2001-04-12 | Novartis Ag | Wirkstoffabgabevorrichtung mit gesteuerter Freigabe |
US5635210A (en) * | 1994-02-03 | 1997-06-03 | The Board Of Regents Of The University Of Oklahoma | Method of making a rapidly dissolving tablet |
US6103263A (en) * | 1994-11-17 | 2000-08-15 | Andrx Pharmaceuticals, Inc. | Delayed pulse release hydrogel matrix tablet |
HU226586B1 (en) * | 1998-12-16 | 2009-04-28 | Aventis Pharma Inc | Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
US6469007B2 (en) * | 2000-11-28 | 2002-10-22 | Wyeth | Serotonergic agents |
RU2315044C2 (ru) * | 2002-03-12 | 2008-01-20 | Уайт | Способ получения хиральных 1,4-дизамещенных пиперазинов |
KR20040091720A (ko) * | 2002-03-12 | 2004-10-28 | 와이어쓰 | N1-(2'-피리딜)-1,2-프로판디아민 설팜산의 제조방법 및생물학적 활성 피페라진 합성시의 이의 용도 |
MXPA04008729A (es) * | 2002-03-12 | 2005-07-13 | Wyeth Corp | Proceso para sintetizacion de piperazinas n-arilicas quirales. |
US7361773B2 (en) * | 2002-03-12 | 2008-04-22 | Wyeth | Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
AR045068A1 (es) * | 2003-07-23 | 2005-10-12 | Univ Missouri | Formulacion de liberacion inmediata de composiciones farmaceuticas |
-
2005
- 2005-03-17 US US11/082,548 patent/US20050215561A1/en not_active Abandoned
- 2005-03-18 KR KR1020067021638A patent/KR20070085090A/ko not_active Application Discontinuation
- 2005-03-18 WO PCT/US2005/009142 patent/WO2005092307A2/en active Application Filing
- 2005-03-18 PE PE2005000317A patent/PE20060125A1/es not_active Application Discontinuation
- 2005-03-18 JP JP2007504154A patent/JP2007529551A/ja active Pending
- 2005-03-18 EP EP05729568A patent/EP1730139A2/en not_active Ceased
- 2005-03-18 MX MXPA06010730A patent/MXPA06010730A/es not_active Application Discontinuation
- 2005-03-18 CA CA002560243A patent/CA2560243A1/en not_active Abandoned
- 2005-03-18 BR BRPI0508975-1A patent/BRPI0508975A/pt not_active IP Right Cessation
- 2005-03-18 TW TW094108388A patent/TW200539879A/zh unknown
- 2005-03-18 AU AU2005225435A patent/AU2005225435A1/en not_active Withdrawn
-
2006
- 2006-09-13 IL IL178067A patent/IL178067A0/en unknown
- 2006-09-19 EC EC2006006866A patent/ECSP066866A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1730139A2 (en) | 2006-12-13 |
MXPA06010730A (es) | 2007-02-21 |
TW200539879A (en) | 2005-12-16 |
PE20060125A1 (es) | 2006-02-28 |
BRPI0508975A (pt) | 2007-08-28 |
IL178067A0 (en) | 2006-12-31 |
JP2007529551A (ja) | 2007-10-25 |
WO2005092307A3 (en) | 2006-01-19 |
KR20070085090A (ko) | 2007-08-27 |
AU2005225435A1 (en) | 2005-10-06 |
CA2560243A1 (en) | 2005-10-06 |
WO2005092307A2 (en) | 2005-10-06 |
US20050215561A1 (en) | 2005-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066866A (es) | Formas de dosificación y composiciones farmacéuticasreferencia a las solicitudes relacionadas | |
UY29562A1 (es) | Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
UY27740A1 (es) | Nuevos compuestos | |
BR0112756A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto | |
UY30025A1 (es) | Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
UY30327A1 (es) | Nuevos compuestos ii | |
DOP2006000193A (es) | Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso | |
ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
SV2008001369A (es) | Benzimidazoles | |
ECSP077235A (es) | Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa | |
UY28059A1 (es) | Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos. | |
GT200500309A (es) | Derivados de sulfonilbencilimidazol | |
BRPI0513672A (pt) | processo aperfeiçoado para a preparação de 2h-1-benzopiran-2metanol, (alfa). (alfa)' [iminobis (metileno)] bis [6-fluoro-3, 4-dihidro, [2r* [r* [r* (s*)]]]], composição farmacêutica, forma t1 amorfa, e processo para a preparação da forma t1 de hidrocloreto de nebivolol | |
CL2003002762A1 (es) | Compuestos derivados de pirrolopirimidina o pirrolopiridina sustituidas por una amina ciclica, sus sales; composicion farmaceutica; y su uso para preparar un antagonista de los receptores de crf, para tratar enfermedades como depresion, ansiedad, alz | |
UY30460A1 (es) | Compuestos terapéuticos | |
DK1853232T3 (da) | Stabil krystallin form af bifeprunox mesylat, doseringsformer deraf og fremgangsmåder for deres anvendelse | |
BRPI0607811B8 (pt) | derivados de óxido de pirimidina de 2-(4-cianofenilamino) inibidores de hiv, composição farmacêutica compreendendo os mesmos, processo para preparar a referida composição e uso | |
UY29823A1 (es) | Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones | |
PA8514901A1 (es) | Metabolitos agonistas/antagonistas de estrogeno | |
AR052909A1 (es) | Base cristalina del trans-1-((1r,3s)-6-cloro-3-fenilindan-1-il)-3,3-dimetilpiperazina | |
UY29817A1 (es) | Nuevos compuestos de azetidina, composiciones farmacéuticas que los contienen, procesos de preparación y uso terapéutico de los mismos. | |
UY29561A1 (es) | Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
SV2007002357A (es) | Derivado de quinolina, su uso, preparacion y medicamento que lo contiene ref. p-sv-79232/ug | |
UY27998A1 (es) | Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia | |
CR9800A (es) | Formas y composiciones de dosificaciones farmaceuticas |